A detailed history of Qube Research & Technologies LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 36,438 shares of PLX stock, worth $61,944. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,438
Previous 121,030 69.89%
Holding current value
$61,944
Previous $141,000 73.76%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.9 - $1.17 $76,132 - $98,972
-84,592 Reduced 69.89%
36,438 $37,000
Q2 2024

Aug 14, 2024

BUY
$1.1 - $1.32 $133,133 - $159,759
121,030 New
121,030 $141,000

Others Institutions Holding PLX

About Protalix BioTherapeutics, Inc.


  • Ticker PLX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,753,400
  • Market Cap $84.6M
  • Description
  • Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...
More about PLX
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.